Image courtesy of Lincoln Property Co.

A speculative lab project in Waltham landed its largest tenant to date in a Framingham-based biopharma company.

BPGbio will relocate to 300 Third Ave., a 143,533-square-foot lab building overlooking Route 128. The company will occupy two floors in June 2025 at the project, developed by Lincoln Property Co. and a client of MetLife Investment Management.

The lease leaves 36,900 square feet available on the third floor. Developers broke ground on the 4-story lab building in 2021, and Biocytogen leased nearly 37,000 square feet in 2022.

Lincoln Property’s Tim Latham, Christopher Scott and Chris Devaux represented ownership in the transaction. Cresa Boston’s Paul Delaney, Adam Subber, and Nate Heilbron represented the tenant. 

BPGbio was founded by a group of private investors for the acquisition of Framingham-based Berg Health in February.